Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› New York
Clinical trial register · United States · industry-sponsored

Clinical Trials in New York, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9148 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Nov 2026, 03:16 UTC
9148
Studies in scope
industry-sponsored, all four open statuses
4975
Recruiting now
open to new participants
2181
Lead sponsors
across recruiting studies
Top states
California 5328 Florida 4488 Illinois 2493 Georgia 2364 Arizona 2269

Trials with a site in New York

2118 of 9148 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
NCT07197554Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC)
SEED Therapeutics, Inc.
Phase 1
171
California, Massachusetts, New York, Texas
2025-12-01
Not yet open
Kaneka Medical America LLC
Observational
200
New York, Pennsylvania
2025-11-30
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
California, Colorado, Florida, Georgia, Illinois, Indiana, Mississippi, New York
2025-11-28
Recruiting
Distalmotion SA
Observational
140
California, New York, Texas
2025-11-26
Recruiting
Debiopharm International SA
Phase 3
119
California, Illinois, Massachusetts, Missouri, Nevada, New York, Ohio, Oregon
2025-11-26
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301IO Resistant Squamous and Nonsquamous NSCLC
Takeda
Phase 3
1,200
Arkansas, California, District of Columbia, Florida, Missouri, New York, Tennessee, Texas
2025-11-26
Recruiting
PhenoNet, Inc.
Phase 2
105
Arizona, California, Florida, New York
2025-11-25
Active, closed
Amgen
Phase 3
250
California, Florida, Georgia, New York, North Carolina, Ohio, Texas, Washington
2025-11-25
Active, closed
Kymera Therapeutics, Inc.
Phase 2
200
Alabama, Arkansas, California, Florida, Illinois, Michigan, New York, North Dakota
2025-11-24
Recruiting
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
NCT07103018Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients, Metastatic Castration-resistant Prostate Cancer, mCRPC, mCRPC
K36 Therapeutics, Inc.
Phase 1
144
California, Florida, Minnesota, New York, North Carolina, Ohio, South Carolina, Texas
2025-11-21
Recruiting
Pfizer
Phase 2
165
Arizona, California, Florida, New York, Ohio, Pennsylvania
2025-11-20
Active, closed
Pfizer
Phase 3
207
New Jersey, New York, Pennsylvania
2025-11-19
Recruiting
BioNTech SE
Phase 1/2
245
Colorado, Florida, Michigan, New York
2025-11-18
Recruiting
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
NCT07192432HER2 Expressing Solid Tumors
Vironexis Biotherapeutics Inc.
Phase 1/2
27
California, Colorado, Florida, Minnesota, New Jersey, New York, Ohio, Pennsylvania
2025-11-18
Recruiting
B-FREE Chronic Babesiosis Study
NCT06656351Chronic Babesiosis
60 Degrees Pharmaceuticals LLC
Phase 2
40
New York
2025-11-18
Recruiting
Everest Medicines (Beijing) Co., Ltd.
Phase 1/2
94
New York, Texas, Virginia
2025-11-17
By invitation
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
NCT07218003Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
Rondo Therapeutics
Phase 1
149
California, Connecticut, Michigan, New York, North Carolina, South Carolina, Tennessee, Texas
2025-11-17
Recruiting
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
NCT07217704Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
SOFIE
Phase 3
200
California, Florida, Illinois, Indiana, Massachusetts, Minnesota, New York, Ohio
2025-11-14
Recruiting
Nitinotes Surgical Ltd.
Not applicable
184
California, Florida, New York
2025-11-14
Recruiting
ACADIA Pharmaceuticals Inc.
Phase 3
126
California, District of Columbia, Florida, Hawaii, Kansas, New York, Ohio, Oklahoma
2025-11-14
Active, closed
Boehringer Ingelheim
Phase 2
81
Alabama, Florida, Iowa, Kansas, Minnesota, Missouri, New York, North Carolina
2025-11-13
Active, closed
Hoffmann-La Roche
Phase 2
193
California, Colorado, Florida, Maryland, Massachusetts, New York, Tennessee, Washington
2025-11-13
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
NCT07217171Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma
EvolveImmune United, Inc
Phase 1
160
California, Connecticut, Georgia, Michigan, New York, North Carolina, Ohio, Pennsylvania
2025-11-13
Active, closed
Actinium Therapy for Late-stage Aggressive Sarcomas
NCT07156565Advanced Soft Tissue Sarcoma
Ratio Therapeutics, Inc.
Phase 1
48
California, Minnesota, New York, Ohio, Texas
2025-11-12
By invitation
Rhythm Pharmaceuticals, Inc.
Phase 2
25
Colorado, Iowa, Massachusetts, New York, North Carolina, Tennessee
2025-11-10
Recruiting
Regeneron Pharmaceuticals
Phase 3
20
Arizona, California, Colorado, Georgia, Massachusetts, New York, North Carolina, Pennsylvania
2025-11-10
Recruiting
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1
710
Arizona, California, Florida, Louisiana, Maryland, Mississippi, New York, North Carolina
2025-11-08
Recruiting
Avisi Technologies Inc.
Not applicable
165
Arizona, California, Colorado, New York, Pennsylvania, Texas, Wisconsin
2025-11-07
Recruiting
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT07227168Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer
Sutro Biopharma, Inc.
Phase 1
200
California, Colorado, District of Columbia, Florida, Massachusetts, New York, Texas, Virginia
2025-11-07
Active, closed
Boston Scientific Corporation
Not applicable
699
Arkansas, California, Georgia, Idaho, New York, Ohio, Pennsylvania, Texas
2025-11-07
Recruiting
Brainsway
Not applicable
186
Alabama, California, Florida, Illinois, New York, Ohio, Oregon, South Carolina
2025-11-07
Recruiting
Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control
NCT07190807Chronic Pain, Intractable Pain, Low Back Pain, Chronic Low-back Pain
Boston Scientific Corporation
Not applicable
70
Colorado, Florida, Louisiana, New York, Pennsylvania, South Carolina, Texas
2025-11-07
Recruiting
Pfizer
Phase 1
294
Alabama, Florida, Georgia, Illinois, Iowa, Kansas, New Jersey, New York
2025-11-06
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
65
Colorado, Florida, Illinois, Massachusetts, Missouri, New Jersey, New York, Ohio
2025-11-06
Recruiting
Agitated Solutions, Inc.
Phase 3
300
Illinois, Minnesota, Mississippi, New York, Wisconsin
2025-11-05
Active, closed
Novo Nordisk A/S
Phase 3
330
Alabama, Arizona, California, Florida, Hawaii, Indiana, Nevada, New York
2025-11-05
Active, closed
The Effect of Hydration Status on Substrate Oxidation at Rest and During Light and Moderate Exercise
NCT07298863Hydration Status, Substrate Metabolism During Exercise
PepsiCo Global R&D
Not applicable
104
New York
2025-11-05
Recruiting
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
NCT07189403Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer
Daiichi Sankyo
Phase 1
40
Florida, New York, Rhode Island
2025-11-04
Active, closed
Vasa Therapeutics
Phase 1
42
Arkansas, California, Florida, Illinois, Louisiana, Missouri, New Jersey, New York
2025-11-04
Active, closed
Takeda
Phase 2
207
Arkansas, California, Florida, Louisiana, Maryland, Michigan, New York, South Carolina
2025-11-03
Recruiting
Eli Lilly and Company
Phase 2
222
Arkansas, Florida, Georgia, Michigan, Missouri, Nevada, New York, South Carolina
2025-11-03
Recruiting
EBR Systems, Inc.
Observational
320
Arizona, Arkansas, Florida, Michigan, Missouri, New York, Ohio, Pennsylvania
2025-11-03
Recruiting
SAINT in Postpartum Depression (PPD)
NCT07210255Postpartum Depression (PPD)
Magnus Medical
Not applicable
192
Massachusetts, New York, South Carolina, Texas
2025-11-01
Active, closed
Bausch Health Americas, Inc.
Not applicable
164
California, Illinois, Massachusetts, New York, Texas
2025-10-31
Recruiting
Pfizer
Phase 2
200
Arizona, Arkansas, California, Colorado, Illinois, Maryland, Michigan, New York
2025-10-30
Recruiting
AstraZeneca
Phase 3
100
Florida, Indiana, Nebraska, New York, Texas, Washington
2025-10-30
Active, closed
Abbott Medical Devices
Not applicable
11
Kansas, Minnesota, New York
2025-10-30
Active, closed
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
NCT07217860Bipolar Depression, Bipolar I Disorder, Bipolar Disorder, Bipolar II Disorder
Xenon Pharmaceuticals Inc.
Phase 3
400
Arkansas, California, Florida, Georgia, Illinois, New Jersey, New York, Pennsylvania
2025-10-30
Active, closed
SPI-1005 for the Treatment of Meniere's Disease (Open Label)
NCT06859788Meniere's Disease, Ménière's Disease
Sound Pharmaceuticals, Incorporated
Phase 3
200
California, Florida, New York, Pennsylvania, South Carolina, Texas, Wisconsin
2025-10-29
Recruiting
Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD
NCT06878560ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation
United Therapeutics
Phase 1/2
50
Illinois, New York
2025-10-29
Recruiting
Novartis Pharmaceuticals
Phase 2
165
Mississippi, New Jersey, New York, North Carolina, Utah, Washington
2025-10-28
Recruiting
Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients
NCT07110636Infection, Infections, Bacterial, Infections, Fungal, Infection Viral
Karius, Inc.
Not applicable
2,000
California, Louisiana, Massachusetts, Nebraska, New York
2025-10-27
By invitation
Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
NCT07287163Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure
Praxis Precision Medicines
Phase 3
700
Florida, Louisiana, Maryland, Michigan, Missouri, New Jersey, New York, Pennsylvania
2025-10-27
Active, closed
Bavarian Nordic
Phase 2
970
Iowa, Kansas, New York, North Carolina, South Carolina, Tennessee, Texas, Virginia
2025-10-27
Recruiting
Takeda
Phase 3
70
Arizona, California, Illinois, Michigan, New Jersey, New York, Ohio, Oklahoma
2025-10-27
Recruiting
Criterium, Inc.
Phase 2
120
Connecticut, Florida, New Jersey, New York, Pennsylvania, South Carolina, Tennessee, Texas
2025-10-27
Recruiting
AbbVie
Phase 3
395
Arizona, California, Connecticut, Georgia, Maryland, New York, North Carolina, Texas
2025-10-24
Recruiting
Sanofi
Phase 3
60
California, District of Columbia, Illinois, Louisiana, Massachusetts, Michigan, Minnesota, New York
2025-10-24
Recruiting
The Short Sleep Study
NCT07567560Short Sleepers
Danisco
Observational
34
Florida, Massachusetts, New York, Texas
2025-10-23
Recruiting
ITF Therapeutics LLC
Observational
300
Arkansas, District of Columbia, Illinois, Massachusetts, New York, North Carolina, Oregon, Washington
2025-10-23
By invitation
Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)
NCT07221565Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases
Truway Health, Inc.
Phase 1/2
120
New York
2025-10-23
Recruiting
Ankyra Therapeutics, Inc
Phase 1
60
Florida, Illinois, Indiana, Michigan, Minnesota, New York, North Carolina, Pennsylvania
2025-10-22
Recruiting
Efforia, Inc
Not applicable
100
New York
2025-10-21
Recruiting
Efforia, Inc
Not applicable
100
New York
2025-10-21
Recruiting
Pivotal Study of the Velocity™ pAVF System
NCT07153939Chronic Kidney Disease, Hemodialysis Access, Arteriovenous Fistula, End Stage Renal Disease (ESRD)
Venova Medical
Not applicable
126
Alabama, California, Florida, New York, North Carolina, South Carolina, Texas
2025-10-21
Recruiting
A Study of ZW251 in Participants With Advanced Solid Tumors
NCT07164313Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
Zymeworks BC Inc.
Phase 1
140
California, Kentucky, Michigan, New Jersey, New York, Texas
2025-10-21
Recruiting
A Study to Characterize Human Skin Changes From Biostimulator Treatments Via Non-invasive Imaging
NCT07399028Volume Deficiency in the Mid-Face, Skin Laxity, Photo-aged Skin
Galderma R&D
Not applicable
25
New York
2025-10-21
Active, closed
Bausch Health Americas, Inc.
Not applicable
49
California, Florida, Illinois, New York, Texas
2025-10-17
Active, closed
Efforia, Inc
Not applicable
100
New York
2025-10-17
Recruiting
NuScience Medical Biologics, LLC
Not applicable
132
Louisiana, Mississippi, New York
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
1,100
Arizona, Arkansas, California, Florida, Illinois, Maryland, Massachusetts, New York
2025-10-16
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
25
Massachusetts, New York, North Carolina
2025-10-16
Active, closed
Genentech, Inc.
Phase 1
60
California, Missouri, New Jersey, New York
2025-10-15
Recruiting
ImmunityBio, Inc.
Phase 1/2
40
Arizona, California, Georgia, Michigan, New York, Pennsylvania, Tennessee, Virginia
2025-10-15
Recruiting
HemoSphere Alta Study
NCT07148323Hemodynamic Instability
Becton, Dickinson and Company
Observational
100
New York
2025-10-14
Recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
NCT07174583Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3
IDEAYA Biosciences
Phase 1/2
262
Colorado, Florida, Indiana, Michigan, New York, Pennsylvania, Tennessee, Texas
2025-10-14
By invitation
Healthcare Integrity & Anti-Fraud Enforcement
NCT07217730Healthcare Fraud Schemes, Kickback Networks, Supply Chain Vulnerabilities, Governance Failures
Truway Health, Inc.
Observational
100
New York
2025-10-13
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 1
77
Connecticut, New York, Texas
2025-10-10
By invitation
Novel On-body Evaluation of Cardiac Health for Oncology
NCT07158450Cardiotoxicity, Heart Failure
Skribe Medical
Observational
1,000
Colorado, Florida, Illinois, Louisiana, New York, Pennsylvania, Tennessee, Virginia
2025-10-09
Recruiting
Sanmai Technologies PBC dba Sanmai
Not applicable
60
Arizona, California, Florida, New York
2025-10-08
Recruiting
Bristol-Myers Squibb
Phase 3
424
Arkansas, California, Florida, Georgia, Illinois, Indiana, Missouri, New York
2025-10-08
Recruiting
CatalYm GmbH
Phase 2
131
Alabama, California, New York, North Carolina
2025-10-07
Active, closed
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
NCT07219121Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis, Kidney Transplant
Travere Therapeutics, Inc.
Phase 4
20
Alabama, New York, North Carolina, Ohio, Texas, Washington, Wisconsin
2025-10-07
Recruiting
A Study of CTD402 in T-ALL/LBL Patients
NCT07070219Acute Lymphocytic Leukemia Refractory, Lymphoma, Lymphoblastic
Imviva Bio
Phase 1/2
118
California, Colorado, Illinois, Minnesota, New York, Tennessee, Texas
2025-10-07
By invitation
Deployment and Evaluation of Humanoid Robotics in Coalition-Aligned Clinical Care Settings
NCT07214896Mobility Impairment, Clinical Workflow Optimization, Sanitation Protocol Compliance, ESG-linked Healthcare Robotics Deployment
Truway Health, Inc.
Phase 2
400
New York, Texas
2025-10-06
Recruiting
Diality Inc.
Not applicable
50
California, New York, Tennessee, Texas, Washington
2025-10-06
Recruiting
Efforia, Inc
Not applicable
100
New York
2025-10-06
Recruiting
Janssen Research & Development, LLC
Phase 2
60
California, Florida, Iowa, New York, North Carolina, Ohio
2025-10-03
Recruiting
Avenzo Therapeutics, Inc.
Phase 1/2
355
California, Colorado, Connecticut, Florida, Massachusetts, New York, North Carolina, Ohio
2025-10-02
Active, closed
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
NCT07033481Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
EIP Pharma Inc
Phase 2
20
Illinois, Minnesota, New York, Ohio, Pennsylvania
2025-10-02
Recruiting
Incyte Corporation
Phase 1
120
Arizona, California, Colorado, Florida, Illinois, Maryland, New York, North Carolina
2025-10-01
Recruiting
Urotronic Inc.
Not applicable
60
California, Florida, Indiana, New York, Texas, Utah
2025-10-01
Recruiting
Ponce Medical School Foundation, Inc.
Not applicable
125
New Jersey, New York
2025-10-01
By invitation
Truway Diagnostic Tools in Primary Care
NCT07209527Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute
Truway Health, Inc.
Early Phase 1
200
New York
2025-10-01
Recruiting
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
NCT06910306Recurrent Glioblastoma, Recurrent Gliomas
Alpha Tau Medical LTD.
Not applicable
20
Arizona, New York, Ohio
2025-10-01
Recruiting
AstraZeneca
Phase 1/2
283
Arkansas, California, Maryland, Massachusetts, Michigan, New York, Rhode Island, South Carolina
2025-10-01
Recruiting
Cullinan Therapeutics Inc.
Phase 1
36
Florida, New York, Tennessee, Texas, Utah
2025-10-01
Recruiting
AstraZeneca
Phase 1/2
52
Florida, Massachusetts, Michigan, New York, Rhode Island
2025-09-30
Recruiting
ModernaTX, Inc.
Phase 1/2
190
Alabama, California, Georgia, Massachusetts, New York, North Carolina, Pennsylvania, Tennessee
2025-09-30
Active, closed
Synaptrix, Inc.
Not applicable
123
Alabama, New York, North Carolina, Oregon, Washington
2025-09-30
Recruiting
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
200
California, Florida, Illinois, Kansas, New York, North Carolina, Pennsylvania, Washington
2025-09-30
Recruiting
Safety and Efficacy of wSp Vaccine in Young Children
NCT07216430Acute Otitis Media (AOM)
Serum Life Science Europe GmbH
Phase 2
320
New York
2025-09-29
Recruiting
TLN-372 in Advanced KRAS Mutant Solid Tumors
NCT07204340KRAS Mutant Solid Tumors
Treeline Biosciences, Inc.
Phase 1
270
Alabama, Massachusetts, Michigan, Missouri, New York, Tennessee
2025-09-29
Recruiting
Genentech, Inc.
Phase 2
224
California, Colorado, Florida, Illinois, New York, North Carolina, Utah
2025-09-29
Recruiting
Sanofi
Phase 3
124
California, Florida, Georgia, Massachusetts, Michigan, Minnesota, New York, North Carolina
2025-09-26
Active, closed
SPHERE Per-AF Post-Approval Study
NCT06858306Persistent Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
200
Alabama, Florida, Georgia, Minnesota, New York, North Carolina, Ohio, Pennsylvania
2025-09-25
Recruiting
Efforia, Inc
Not applicable
100
New York
2025-09-25
Recruiting
Efforia, Inc
Not applicable
100
New York
2025-09-25
Recruiting
Opus Genetics, Inc
Phase 1/2
10
California, Florida, New York, Ohio, Texas
2025-09-25
Recruiting
A Multi-Center Study Assessing the Safety and Efficacy of the LEGION Medial Stabilized (MS) Insert in Patients Undergoing a Total Knee Arthroplasty (TKA)
NCT07199738Inflammatory Arthritis, Primary Total Knee Arthroplasty Due to Degenerative Joint Disease (Primary Diagnosis of Osteoarthritis), Post-traumatic Arthritis
Smith & Nephew, Inc.
Observational
144
Massachusetts, New York, South Carolina, Wisconsin
2025-09-25
Recruiting
AstraZeneca
Phase 1/2
164
California, Florida, Minnesota, New York, Ohio, South Carolina, Tennessee
2025-09-24
Active, closed
Stratagen Bio, Inc.
Not applicable
75
New York, Virginia
2025-09-24
Recruiting
Novartis Pharmaceuticals
Phase 1
20
California, Florida, Illinois, New York, North Carolina, Ohio, Oregon, Pennsylvania
2025-09-24
Recruiting
Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome
NCT06776783Respiratory Distress Syndrome, Pre-term Infants
Aerogen Pharma Limited
Phase 3
520
Arkansas, California, Florida, Indiana, Maryland, Massachusetts, New Jersey, New York
2025-09-24
Recruiting
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
NCT06760546Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia
Rhythm Pharmaceuticals, Inc.
Phase 3
39
Alabama, Colorado, Illinois, Massachusetts, Minnesota, New York, Pennsylvania, Washington
2025-09-23
Recruiting
Efforia, Inc
Observational
100
New York
2025-09-22
Recruiting
MMI (Medical Microinstruments, Inc.)
Observational
455
California, Connecticut, Florida, New Jersey, New York, Ohio, South Carolina
2025-09-22
Recruiting
Bristol-Myers Squibb
Observational
300
California, Florida, Illinois, Maryland, Massachusetts, Nebraska, New Jersey, New York
2025-09-22
Recruiting
BioNTech SE
Phase 1/2
880
California, Connecticut, District of Columbia, Florida, Massachusetts, Michigan, New York, Ohio
2025-09-22
Active, closed
Danisco
Not applicable
174
Florida, Massachusetts, New York
2025-09-17
Recruiting
Amgen
Phase 1
380
Arizona, California, Florida, Georgia, Kentucky, Massachusetts, Missouri, New York
2025-09-16
Active, closed
Recens Medical, Inc.
Not applicable
15
New York
2025-09-16
Recruiting
CSL Behring
Phase 3
200
California, Georgia, Illinois, Kansas, Maryland, New Jersey, New York, Ohio
2025-09-15
Active, closed
A Study in Subjects With Neurogenic Orthostatic Hypotension
NCT07089043Neurogenic Orthostatic Hypotension
CuraSen Therapeutics, Inc.
Phase 2
12
Arizona, Michigan, New Jersey, New York, Tennessee
2025-09-12
Recruiting
AMEND TS Early Feasibility Study
NCT06951672Symptomatic Functional MR 3 or Greater
Valcare Medical Ltd.
Not applicable
15
Arizona, California, Georgia, Indiana, New York, Oregon, Tennessee, Texas
2025-09-11
Recruiting
LEO Pharma
Phase 2
135
California, Georgia, Michigan, New York, Ohio, Oregon, Pennsylvania
2025-09-11
By invitation
Efforia, Inc
Not applicable
100
New York
2025-09-11
Recruiting
Efforia, Inc
Not applicable
100
New York
2025-09-10
Recruiting
Efforia, Inc
Not applicable
100
New York
2025-09-10
By invitation
Digital Physical Activity Program
NCT07179796Overall Health, Wellbeing, Quality of Life, Mental Health
Sword Health, SA
Observational
300,000
New York
2025-09-09
Recruiting
Bristol-Myers Squibb
Phase 2
182
Alaska, Massachusetts, Michigan, Missouri, New York, Ohio, Oregon, Washington
2025-09-09
Recruiting
TScan Therapeutics, Inc.
Observational
1,000
California, New York
2025-09-09
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
NCT06689839Aortic Stenosis Treated With TAVI, Aortic Diseases
EnCompass Technologies, Inc.
Not applicable
500
Florida, Indiana, Michigan, Missouri, New York, Ohio, Virginia
2025-09-09
By invitation
Digital Care Programs for Mental Health
NCT07183085Mental Distress, Mental Resilience
Sword Health, SA
Observational
300,000
New York
2025-09-09
Recruiting
Efforia, Inc
Not applicable
100
New York
2025-09-09
Recruiting
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
NCT06919354Type 1 Diabetes (T1D), Type 1 Diabetes Mellitus
GentiBio, Inc
Phase 1
16
California, Florida, Massachusetts, New York, North Carolina
2025-09-03
By invitation
Seaport Therapeutics
Phase 2
360
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2025-09-02
Recruiting
Microvascular Obstruction Diagnosis Using the CoFI™ System Assessment - II
NCT06909578Microvascular Obstruction (MVO), STEMI - ST Elevation Myocardial Infarction, PPCI
CorFlow Therapeutics AG
Not applicable
236
California, Delaware, Illinois, Michigan, Minnesota, New York, North Carolina, Ohio
2025-09-01
Recruiting
Efforia, Inc
Not applicable
100
New York
2025-08-29
Recruiting
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)
ADARx Pharmaceuticals, Inc.
Phase 2
85
Florida, Iowa, Louisiana, Michigan, New York, Ohio, South Dakota, Texas
2025-08-28
Recruiting
Azitra Inc.
Phase 1/2
32
Arkansas, Connecticut, New York, Ohio, Texas, Virginia
2025-08-25
Recruiting
Climb Bio, Inc.
Phase 2
45
Colorado, Florida, Georgia, Indiana, New York, Texas
2025-08-25
Recruiting
Efforia, Inc
Not applicable
100
New York
2025-08-25
Recruiting
Efforia, Inc
Not applicable
100
New York
2025-08-25
By invitation
Efforia, Inc
Not applicable
100
New York
2025-08-25
By invitation
Morning Water Study
NCT07256587Energy
Efforia, Inc
Not applicable
100
New York
2025-08-23
Recruiting
Eli Lilly and Company
Not applicable
7,000
New York
2025-08-22
Recruiting
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
NCT07020117Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer
Aktis Oncology, Inc.
Phase 1
150
California, Florida, Iowa, Kansas, Maryland, Michigan, New York, Pennsylvania
2025-08-22
Recruiting
Nuvation Bio Inc.
Phase 3
180
California, District of Columbia, Florida, Idaho, Louisiana, Massachusetts, Minnesota, New York
2025-08-21
Active, closed
Pulse Biosciences, Inc.
Not applicable
103
Florida, New York
2025-08-21
Recruiting
Avenzo Therapeutics, Inc.
Phase 1/2
380
California, Connecticut, Florida, Massachusetts, New York, Ohio, Tennessee, Texas
2025-08-20
Recruiting
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT07081646Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis
Alexion Pharmaceuticals, Inc.
Phase 1/2
91
Arizona, California, Florida, Massachusetts, Michigan, Minnesota, Missouri, New York
2025-08-18
Active, closed
PSMA PET Combined With MRI for the Detection of PCa
NCT07052214PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
338
California, Florida, Illinois, Indiana, Louisiana, Missouri, New York, Pennsylvania
2025-08-18
Recruiting
Neurocrine Biosciences
Phase 3
550
California, Connecticut, Florida, Iowa, Louisiana, Missouri, New Mexico, New York
2025-08-18
Recruiting
Efforia, Inc
Not applicable
100
New York
2025-08-15
Recruiting
Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.
NCT07209475Diabetic Foot Ulcer (DFU), Amnio-Maxx
Royal Biologics
Phase 4
248
California, Florida, Georgia, Nebraska, New York, Oklahoma, Texas
2025-08-14
Recruiting
GlaxoSmithKline
Phase 2
220
Florida, New Jersey, New York, North Carolina, Oklahoma, Texas, Virginia
2025-08-14
Recruiting
Kedrion S.p.A.
Phase 3
40
California, New York, North Carolina
2025-08-13
Recruiting
Galderma R&D
Not applicable
40
Florida, New York
2025-08-12
Active, closed
Pfizer
Phase 1
200
California, Florida, New York, Ohio, Tennessee
2025-08-11
Recruiting
Merck Sharp & Dohme LLC
Phase 2
250
Alaska, Florida, Louisiana, Nebraska, New Jersey, New York, Ohio, Texas
2025-08-11
Recruiting
Self-balancing Personal Exoskeleton for SCI (WINY)
NCT07222033Spinal Cord Injury, Paraplegia and Tetraplegia
Wandercraft
Not applicable
12
New York
2025-08-11
Recruiting
GlaxoSmithKline
Phase 3
420
California, Florida, Illinois, New York, North Carolina, Ohio, Texas
2025-08-11
Recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1
52
California, Colorado, Illinois, Massachusetts, New York, Tennessee
2025-08-11
Active, closed
GlaxoSmithKline
Phase 2
168
Kentucky, Missouri, Nebraska, New York, Pennsylvania, Texas
2025-08-06
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
California, Florida, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania
2025-08-06
By invitation
Elumn8 Medical
Not applicable
115
Georgia, Minnesota, New York, Texas
2025-08-06
Recruiting
ACADIA Pharmaceuticals Inc.
Phase 2
180
California, Colorado, District of Columbia, Florida, Hawaii, Illinois, Kansas, New York
2025-08-06
Active, closed
Baymatob Operations Pty Ltd
Not applicable
1,000
Colorado, Louisiana, New York, Ohio, Pennsylvania
2025-08-06
Active, closed
Ensoma
Phase 1/2
15
California, Florida, Massachusetts, Minnesota, New York, North Carolina, Utah
2025-08-05
Recruiting
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT06997029Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
Bristol-Myers Squibb
Phase 1
234
Alabama, California, Colorado, Massachusetts, Missouri, New Hampshire, New York, Texas
2025-08-01
Recruiting
CatalYm GmbH
Phase 2
107
Alabama, California, Connecticut, Florida, New York, North Carolina, South Carolina
2025-08-01
Recruiting
Severe Label Expansion for EVO Products Trial
NCT07090395Obstructive Sleep Apnea
ProSomnus Sleep Technologies
Not applicable
49
New York, Texas
2025-08-01
By invitation
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
NCT06885424Solid Tumor Cancer, Solid Tumor, Unspecified, Adult, Colorectal Carcinoma, Colorectal Carcinoma (CRC)
A2 Biotherapeutics Inc.
Observational
400
Arizona, California, Minnesota, New York
2025-07-31
Recruiting
Gilead Sciences
Phase 1/2
200
California, Kentucky, Maryland, New York
2025-07-31
Recruiting
Inspire Medical Systems, Inc.
Observational
70
Colorado, Florida, Illinois, Kansas, New York
2025-07-31
By invitation
Supernus Pharmaceuticals, Inc.
Phase 2
100
Arizona, California, Florida, New York, North Carolina, Pennsylvania
2025-07-30
Recruiting
AbbVie
Phase 2
377
California, Colorado, Minnesota, New Jersey, New York, Ohio, Oklahoma, Oregon
2025-07-30
Active, closed
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 1
240
California, Florida, Illinois, Indiana, Massachusetts, Missouri, New Jersey, New York
2025-07-28
Recruiting
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT06858319Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis
Novartis Pharmaceuticals
Phase 3
220
Colorado, Florida, Iowa, New York, Tennessee, Texas
2025-07-28
Recruiting
ACTengine® IMA203 Combined With mRNA-4203
NCT06946225Cutaneous Melanoma, Synovial Sarcoma
Immatics US, Inc.
Phase 1
15
California, Massachusetts, New York, Texas
2025-07-25
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Astellas Pharma Inc
Phase 1
404
California, Georgia, Louisiana, Michigan, Missouri, New Jersey, New York, Ohio
2025-07-25
Recruiting
Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems
NCT06959277Peripheral Neuropathies, Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathy With Type 2 Diabetes, Balance Control in Elderly
RxFunction Inc.
Not applicable
200
Arizona, Massachusetts, Minnesota, New York, Pennsylvania, Texas
2025-07-24
Recruiting
AbbVie
Phase 1/2
325
California, Connecticut, Massachusetts, Michigan, New York, North Carolina, Oregon, Texas
2025-07-23
Active, closed
Insmed Gene Therapy LLC
Phase 1
12
Arkansas, California, Georgia, New York, Ohio, Tennessee, Virginia
2025-07-22
Active, closed
Pfizer
Phase 1
380
California, Florida, Kansas, Missouri, Nebraska, New York, North Carolina, Ohio
2025-07-22
Active, closed
Compugen Ltd
Phase 1/2
60
Georgia, Illinois, Massachusetts, Michigan, New York, North Carolina, Ohio, Oklahoma
2025-07-21
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
140
California, New York, North Carolina, Pennsylvania, Tennessee
2025-07-20
Recruiting
DualityBio Inc.
Phase 2
750
California, Colorado, Florida, Georgia, Maryland, Nebraska, New York, Oregon
2025-07-18
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
PharmaEssentia
Phase 3
160
California, District of Columbia, Kansas, Maryland, Missouri, New York, North Carolina, Ohio
2025-07-18
Recruiting
Teleflex
Not applicable
150
California, Kansas, Massachusetts, Michigan, Missouri, New York, Texas, West Virginia
2025-07-18
Recruiting
Daiichi Sankyo
Phase 2
130
Alabama, California, Maryland, Massachusetts, New Jersey, New York, North Carolina, Pennsylvania
2025-07-18
Recruiting
AstraZeneca
Phase 2
100
Delaware, District of Columbia, Kansas, Michigan, New York, Pennsylvania
2025-07-17
Recruiting
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
NCT06994676High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Crossbow Therapeutics, Inc.
Phase 1
72
California, Florida, Illinois, Massachusetts, Missouri, New York, Pennsylvania, Tennessee
2025-07-16
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
Amgen
Phase 2
220
Arizona, Colorado, Florida, Louisiana, Massachusetts, Minnesota, New York, Ohio
2025-07-16
Recruiting
Janssen Research & Development, LLC
Phase 1
400
Florida, New York, Tennessee, Virginia
2025-07-15
Recruiting
Biostar Pharma, Inc.
Phase 2
120
California, Colorado, Georgia, Illinois, Maryland, Nevada, New York, Texas
2025-07-14
Active, closed
ViiV Healthcare
Phase 1
107
California, Florida, Illinois, Missouri, New York, Ohio, Pennsylvania, Texas
2025-07-10
Recruiting
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
NCT06895070Heart Transplant, Heart Failure, Transplant; Failure, Heart
XVIVO Perfusion
Not applicable
60
California, Georgia, Illinois, Missouri, Nebraska, New York, North Carolina, Tennessee
2025-07-10
Recruiting
Imunon
Phase 3
500
Florida, Louisiana, Michigan, Minnesota, Missouri, New York, Oregon, South Dakota
2025-07-09
Active, closed
Glycomine, Inc.
Phase 2/3
50
Minnesota, New York, Pennsylvania, Washington
2025-07-09
Recruiting
XyloCor Therapeutics, Inc.
Phase 2
106
Alabama, Arizona, Georgia, Massachusetts, Michigan, Minnesota, New York, North Carolina
2025-07-08
Recruiting
Bonafide Health
Not applicable
210
New York
2025-07-07
Recruiting
Uro-1 Medical
Not applicable
200
New York, North Carolina, South Carolina
2025-07-07
Active, closed
Sanofi
Phase 2
105
Alabama, California, Florida, Georgia, Iowa, Massachusetts, Missouri, New York
2025-07-07
Recruiting
Janssen Research & Development, LLC
Phase 1
140
Florida, New York, Ohio, Washington
2025-07-07
Active, closed
Novartis Pharmaceuticals
Phase 2
138
California, Colorado, Connecticut, Indiana, Massachusetts, Nebraska, New York, Pennsylvania
2025-07-03
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
360
California, District of Columbia, Michigan, New York, Pennsylvania, Tennessee, Washington
2025-07-03
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Arizona, California, Connecticut, Kansas, Michigan, New York, North Carolina, Ohio
2025-07-02
Recruiting
Study With Phage for CF Subjects With Pseudomonas Lung Infection
NCT06998043Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
BiomX Ltd
Phase 2
63
Alabama, Alaska, Arkansas, California, Colorado, Florida, New Jersey, New York
2025-07-02
By invitation
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
NCT07038447Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis, Idiopathic Inflammatory Myopathy
Kite, A Gilead Company
Phase 1
52
California, Florida, New York
2025-07-02
Active, closed
Immunovant Sciences GmbH
Phase 2
180
California, Colorado, Florida, Illinois, Louisiana, New York, Pennsylvania, Tennessee
2025-06-30
Recruiting
Ipsen
Phase 2
132
Arizona, California, Florida, Georgia, Illinois, Michigan, New York, Washington
2025-06-30
Recruiting
Centessa Pharmaceuticals (UK) Limited
Phase 1
208
Nebraska, New Jersey, New York
2025-06-30
Recruiting
Vektor Medical
Not applicable
423
Arkansas, Florida, Georgia, Indiana, Kentucky, New York, Ohio, Pennsylvania
2025-06-27
By invitation
Clinical Evaluation of an Augmented Reality Intraprocedural Needle Guidance Platform for Soft Tissue Biopsy
NCT07046832Oncology, Interventional Radiology, Liver Carcinoma, Renal Carcinoma
MediView XR, Inc.
Not applicable
104
District of Columbia, New York
2025-06-27
Recruiting
ReproNovo Aps
Phase 2
200
California, New York, Ohio
2025-06-27
Recruiting
Pulmotect, Inc.
Phase 2
100
California, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York
2025-06-27
Recruiting
Capso Vision, Inc.
Not applicable
330
California, Florida, Illinois, New York, Ohio
2025-06-26
Recruiting
NGM Biopharmaceuticals, Inc
Phase 2
136
California, Florida, Maryland, New York, Ohio, Texas, Virginia, Wisconsin
2025-06-25
Recruiting
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult
Verastem, Inc.
Phase 1/2
616
California, Maryland, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Tennessee
2025-06-24
Recruiting
Galvanize Therapeutics, Inc.
Observational
1,000
Arizona, California, Florida, New York, North Carolina, Pennsylvania, South Carolina, Texas
2025-06-23
Recruiting
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
NCT07082803Lymphoma, Lymphoma, Non Hodgkin
Treeline Biosciences, Inc.
Phase 1
180
California, Michigan, Missouri, New York, Pennsylvania, Tennessee, Texas
2025-06-23
Active, closed
jCyte, Inc
Phase 2
31
Arizona, California, Florida, Illinois, New Jersey, New York, Texas, Virginia
2025-06-20
Recruiting
Perosphere Technologies Inc.
Observational
150
Connecticut, Maryland, New Jersey, New York
2025-06-20
Recruiting
Seaport Therapeutics
Phase 2
360
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2025-06-19
Active, closed
Arrowhead Pharmaceuticals
Phase 3
70
Illinois, New York, Ohio, Pennsylvania
2025-06-17
Recruiting
Inmagene LLC
Phase 2
405
California, Florida, Illinois, New York, North Carolina, North Dakota, Ohio, Oregon
2025-06-17
Active, closed
Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
NCT06698458Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Alpha Tau Medical LTD.
Not applicable
50
Arizona, California, Florida, Georgia, New York, Texas
2025-06-17
Recruiting
Suninflam Inc
Phase 1
88
Arizona, Florida, Hawaii, Maryland, Michigan, New York, North Carolina, Texas
2025-06-16
Recruiting
Biocomposites Ltd
Phase 2
60
Arizona, Illinois, Michigan, Mississippi, Missouri, Nebraska, New Jersey, New York
2025-06-15
Recruiting
Signum Surgical USA Inc.
Observational
50
Florida, New Jersey, New York, Pennsylvania
2025-06-14
Recruiting
Ferring Pharmaceuticals
Phase 1/2
20
Arizona, California, Florida, Minnesota, New York, Pennsylvania, Texas
2025-06-12
Recruiting
Bristol-Myers Squibb
Phase 3
274
Arkansas, California, Connecticut, Florida, Georgia, Illinois, New York, Ohio
2025-06-11
Recruiting
GlaxoSmithKline
Phase 1/2
346
California, Colorado, New York, North Carolina, Texas, Washington, Wisconsin
2025-06-11
Recruiting
The Prism Conformity Trial for Post-Traumatic Stress Disorder in Adolescents
NCT06854328Post-Traumatic Stress Disorder in Adolescence
GrayMatters Health Ltd.
Not applicable
45
New York
2025-06-11
Recruiting
VSPharmTech Co.,Ltd.
Phase 2
30
Connecticut, New York
2025-06-11
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136Heterozygous Familial Hypercholesterolaemia
AstraZeneca
Phase 3
473
California, Florida, Georgia, Illinois, Louisiana, Nevada, New York, North Carolina
2025-06-10
Recruiting
Cerus Endovascular, Inc.
Not applicable
250
Illinois, Kansas, New York, North Carolina, Pennsylvania, South Carolina, Washington
2025-06-10
Recruiting
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
NCT07038200Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1
Avidity Biosciences, Inc.
Phase 3
200
California, Colorado, Florida, Iowa, Kansas, Maryland, Massachusetts, New York
2025-06-10
Recruiting
HLA Demographics Study in Adults With Type 1 Diabetes
NCT06860516Diabetes Mellitus, Type I
GentiBio, Inc
Observational
200
California, Florida, Massachusetts, New York, North Carolina
2025-06-06
Recruiting
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
NCT06797999Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
Adcendo ApS
Phase 1/2
270
Colorado, Florida, New York, Texas
2025-06-05
Recruiting
Erasca, Inc.
Phase 1
600
California, Colorado, Florida, Georgia, Massachusetts, New York, Texas, Virginia
2025-06-05
Recruiting
Treebough Therapies
Phase 1
20
New York
2025-06-03
Recruiting
Clinical Study of the inQB8 TTVR System (The MonarQ Study)
NCT06611579Tricuspid Valve Regurgitation
inQB8 Medical Technologies, LLC
Not applicable
50
California, Georgia, New York, Pennsylvania, Texas
2025-06-01
Recruiting
MediWound Ltd
Phase 3
216
Arizona, California, District of Columbia, Florida, Massachusetts, New Jersey, New York, Ohio
2025-06-01
Recruiting
W.L.Gore & Associates
Observational
158
Alabama, California, Florida, Minnesota, New Jersey, New York, North Carolina, Ohio
2025-05-30
Recruiting
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
NCT06533579B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Vironexis Biotherapeutics Inc.
Phase 1/2
32
California, Colorado, Florida, Minnesota, New York, North Carolina, Ohio, Oregon
2025-05-30
Recruiting
Debiopharm International SA
Phase 1/2
154
California, Florida, Illinois, Michigan, New York, Ohio, Texas
2025-05-30
Recruiting
Swedish Orphan Biovitrum
Phase 2
156
Arizona, Massachusetts, Minnesota, New York, Ohio, Texas, Utah, Washington
2025-05-28
Recruiting
Biogen
Phase 3
180
Alabama, California, Michigan, New York, North Carolina, Ohio, Tennessee, Texas
2025-05-22
Active, closed
A2 Biotherapeutics Inc.
Phase 1/2
240
Arizona, California, Florida, Minnesota, Missouri, New York, Ohio, Tennessee
2025-05-22
Active, closed
Upstream Bio Inc.
Phase 2
396
California, Florida, Idaho, Maryland, Michigan, Nevada, New York, Ohio
2025-05-21
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Eli Lilly and Company
Phase 4
787
Florida, Georgia, Illinois, Massachusetts, Minnesota, Nebraska, New York, North Carolina
2025-05-20
Recruiting
ARS Pharmaceuticals, Inc.
Phase 4
600
California, District of Columbia, Illinois, Michigan, New York, Ohio
2025-05-20
Recruiting
Eli Lilly and Company
Phase 4
279
Florida, Georgia, Illinois, Massachusetts, Minnesota, Nebraska, New York, North Carolina
2025-05-20
Recruiting
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
NCT06271590Coronary Artery Disease, Native Coronary Artery Stenosis, Cardiovascular Diseases
Concept Medical Inc.
Not applicable
1,605
Arizona, California, Florida, Georgia, Illinois, Mississippi, New Jersey, New York
2025-05-20
Recruiting
DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease
NCT06918808Perianal Fistula Due to Crohn's Disease
DrugDB-3Q
Direct Biologics, LLC
Phase 2
36
Colorado, Missouri, New York, Pennsylvania, Tennessee
2025-05-19
Recruiting
Pfizer
Phase 1
16
District of Columbia, Georgia, Minnesota, Nebraska, New York, North Carolina, Ohio, Oklahoma
2025-05-16
Recruiting
Apogee Therapeutics, Inc.
Phase 2
350
California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan, New York
2025-05-14
Active, closed
CyanVac LLC
Phase 1
60
New York, Ohio, South Carolina
2025-05-14
Recruiting
SLV-154 Treatment of Advanced Cancers
NCT06771219Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer
Solve Therapeutics
Phase 1
250
California, Missouri, New Jersey, New York, Ohio, Pennsylvania, Texas, Washington
2025-05-14
Recruiting
JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women
NCT07238478Joint Discomfort, Joint Pain, Stiffness, Function, Joint Pain, Hot Flashes
Bonafide Health
Not applicable
250
New York
2025-05-14
Active, closed
RADIQAL Study (Radiation Dose and Image Quality Trial)
NCT06944509Coronary Artery Disease
Philips Clinical & Medical Affairs Global
Not applicable
824
Colorado, Georgia, New York
2025-05-14
Recruiting
Dizal Pharmaceuticals
Phase 1
140
New York, Virginia
2025-05-13
Recruiting
Correlating Multispectral Near-Infrared Imaging to Standard Vascular Diagnostics
NCT06899113Vascular Disease, Peripheral, Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer)
MIMOSA Diagnostics Inc.
Observational
60
New York
2025-05-13
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1/2
166
California, Illinois, Michigan, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-05-12
Recruiting
EXoPERT EMERALD Clinical Study
NCT07186296Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer
EXoPERT
Observational
1,400
California, Hawaii, Kentucky, Maryland, New York
2025-05-09
Recruiting
Bambusa Therapeutics
Phase 1
286
Kentucky, New York
2025-05-08
Recruiting
Takeda
Phase 3
59
Arizona, California, Connecticut, Florida, Missouri, New York, North Carolina, Ohio
2025-05-06
Recruiting
TG Therapeutics, Inc.
Phase 1
100
California, Michigan, Nebraska, New York, Ohio, Wisconsin
2025-05-06
Active, closed
Hoffmann-La Roche
Phase 2
285
Alabama, California, Florida, Georgia, Illinois, New York, North Carolina, Ohio
2025-05-05
Recruiting
STORM Therapeutics LTD
Phase 1/2
107
California, Florida, Massachusetts, Michigan, New York, Ohio, Texas, Virginia
2025-05-05
Recruiting
BioNTech SE
Phase 1/2
594
Arizona, California, Colorado, Florida, Iowa, Minnesota, New Jersey, New York
2025-05-02
Recruiting
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
NCT06846606Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Relapsed/Refractory AML, Relapsed Myelodysplastic Syndromes
Auron Therapeutics, Inc.
Phase 1
69
California, Florida, New York, North Carolina, Ohio, Pennsylvania, Tennessee, Texas
2025-05-01
Active, closed
Agios Pharmaceuticals, Inc.
Phase 2
59
Connecticut, District of Columbia, Georgia, Michigan, New York, Pennsylvania, South Carolina, Texas
2025-05-01
Recruiting
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
NCT06952010Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
Exelixis
Phase 1
303
California, Connecticut, Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee
2025-05-01
Recruiting
Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases
NCT06626919Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases
Kite, A Gilead Company
Phase 1
30
California, Florida, Michigan, Minnesota, New York, Ohio, Oregon, Pennsylvania
2025-04-30
Active, closed
Avexitide for Treatment of Post-Bariatric Hypoglycemia
NCT06747468Post Bariatric Hypoglycemia
Amylyx Pharmaceuticals Inc.
Phase 3
75
California, Colorado, Florida, Georgia, Kansas, Massachusetts, New York, North Carolina
2025-04-29
Recruiting
Pacific Edge Limited
Not applicable
1,000
Alabama, California, Florida, Indiana, Louisiana, Maryland, New Jersey, New York
2025-04-29
Recruiting
Fortvita Biologics (USA)Inc.
Phase 1
285
Arizona, Florida, Minnesota, New York, Texas
2025-04-29
Active, closed
Pharming Technologies B.V.
Phase 2
12
Maryland, Massachusetts, New York
2025-04-29
Active, closed
Synthekine
Phase 1
48
Arizona, New Jersey, New York, Ohio
2025-04-29
Recruiting
Stelexis BioSciences
Phase 1
105
California, Colorado, Florida, Massachusetts, Missouri, New York, Ohio, Texas
2025-04-28
Recruiting
Innoviva Specialty Therapeutics
Observational
100
California, Florida, Kansas, Kentucky, Louisiana, New York, Ohio, Pennsylvania
2025-04-28
Active, closed
Hoffmann-La Roche
Phase 1
50
California, Florida, Illinois, Kansas, New York, Pennsylvania, Texas
2025-04-28
Recruiting
Lead-212 PSV359 Therapy for Patients With Solid Tumors
NCT06710756Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer
Perspective Therapeutics
Phase 1/2
112
California, Florida, Kansas, Kentucky, Minnesota, Missouri, Nebraska, New York
2025-04-28
Recruiting
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
NCT07080242Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer, Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
SystImmune Inc.
Phase 1
120
Alabama, California, Colorado, Connecticut, Georgia, Louisiana, New Jersey, New York
2025-04-28
Recruiting
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
NCT06915753Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification
Tyra Biosciences, Inc
Phase 1
125
California, Kansas, Maryland, Massachusetts, Michigan, New York, Tennessee
2025-04-24
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2
83
California, Florida, Illinois, Louisiana, New Mexico, New York, North Carolina, Ohio
2025-04-23
Active, closed
MMA Embolization for Refractory Chronic Migraine
NCT06735833Migraine Disorders
Cerenovus, Part of DePuy Synthes Products, Inc.
Not applicable
31
California, Connecticut, New York, Pennsylvania, Tennessee, West Virginia
2025-04-23
Recruiting
BioNTech SE
Phase 1/2
380
California, Florida, Georgia, Illinois, Michigan, Missouri, New Jersey, New York
2025-04-23
Recruiting
Access Cannulation Trial II
NCT05490225Dialysis; Complications, Vascular Access Complication
Voyager Biomedical
Not applicable
100
Alabama, California, Massachusetts, New York, South Carolina, Texas, Virginia
2025-04-23
Recruiting
Ipsen
Observational
30
California, Missouri, New York, Tennessee, Texas, Utah
2025-04-22
Recruiting
AstraZeneca
Phase 1/2
150
California, Florida, Georgia, Illinois, Maryland, Massachusetts, Missouri, New York
2025-04-21
Active, closed
Pivotal Study of Voro Urologic Scaffold
NCT06873581Radical Prostatectomy, Stress Urinary Incontinence (SUI)
Levee Medical, Inc.
Phase 3
266
Arizona, California, Florida, Illinois, Indiana, Maryland, Mississippi, New York
2025-04-18
Recruiting
Fertilo In Vitro Research Study and Trial
NCT06858111In Vitro Maturation of Oocytes
Gameto, Inc.
Phase 3
500
California, Florida, Maryland, New York, North Carolina, Texas, Utah
2025-04-17
Active, closed
Pfizer
Observational
1
New York
2025-04-16
Recruiting
Pyxis Oncology, Inc
Phase 1/2
220
California, Florida, Illinois, Massachusetts, New York, Oklahoma, Pennsylvania, Texas
2025-04-15
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
605
Connecticut, Kentucky, Louisiana, Massachusetts, New York, Oklahoma, Texas, Utah
2025-04-15
Recruiting
AbbVie
Phase 1
232
California, Illinois, Missouri, New York, Pennsylvania, Tennessee
2025-04-14
Recruiting
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06673017Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
PanTher Therapeutics
Phase 1
26
California, Florida, Michigan, New York, Texas, Washington
2025-04-14
Active, closed
ASCEND CSP IDE Study
NCT06830746Heart Failure, Ventricular Arrythmia
Abbott Medical Devices
Not applicable
414
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Massachusetts, New York
2025-04-11
Recruiting
R3 Vascular Inc.
Not applicable
300
New York
2025-04-11
Recruiting
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
NCT06920043Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
GlaxoSmithKline
Phase 2
42
Arizona, California, Florida, Georgia, Maryland, Missouri, New York, North Carolina
2025-04-09
Active, closed
Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection
NCT06621251Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee
Trellis Bioscience LLC
Phase 2
60
Arizona, California, Florida, Maryland, Massachusetts, New York, North Carolina, Texas
2025-04-08
Recruiting
CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
NCT06708299Recurrent Pericarditis
Cardiol Therapeutics Inc.
Phase 3
110
Arizona, California, Florida, Illinois, Maryland, Massachusetts, Minnesota, New York
2025-04-07
Recruiting
Vifor Pharma, Inc.
Phase 2
36
Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, New York, North Carolina
2025-04-06
Recruiting
The VENTOR Clinical Study
NCT06759389Cardiac Arrest (CA)
CoLabs Medical
Not applicable
25
New York
2025-04-04
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1/2
280
California, Florida, Massachusetts, Missouri, New York, Tennessee, Texas, Washington
2025-04-03
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
Sanofi
Phase 3
300
Alabama, Arizona, Kansas, New York, Pennsylvania
2025-04-01
Recruiting
Cryo NerVe Block Extremity AmputatioN RegIStry for Post Operative and pHantom Limb Pain
NCT06908538Amputation, Amputation of Lower Limb, Amputation of Upper Limb, Amputation, Limb Loss
AtriCure, Inc.
Observational
2,000
Florida, Massachusetts, New Hampshire, New York, North Carolina, Ohio, South Carolina, Wisconsin
2025-04-01
Recruiting
Tissue Repair Gel in Venous Leg Ulcers in AU/US
NCT06707103Venous Leg Ulcer, Venous Ulcer, Venous Stasis Ulcer, Venous Stasis
TR Therapeutics
Phase 3
312
Florida, Michigan, New York, Texas
2025-04
Recruiting
Supernus Pharmaceuticals, Inc.
Observational
120
California, Florida, New York
2025-03-31
Recruiting
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
665
California, Connecticut, Florida, Illinois, Massachusetts, New York, Tennessee, Texas
2025-03-31
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
50
California, Colorado, Florida, Georgia, Louisiana, Michigan, Minnesota, New York
2025-03-31
Recruiting
Nimbus Wadjet, Inc.
Phase 1/2
134
California, Illinois, Kentucky, New York, North Carolina, Ohio, Rhode Island, South Carolina
2025-03-31
Recruiting
A Study of PHST001 in Advanced Solid Tumors
NCT06840886Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma
Pheast Therapeutics
Phase 1
426
California, Colorado, Connecticut, Illinois, Massachusetts, Michigan, New York, North Carolina
2025-03-31
Active, closed
Autobahn Therapeutics, Inc.
Phase 2
35
California, Connecticut, Florida, Illinois, Massachusetts, New Jersey, New York, Washington
2025-03-28
Recruiting
Prescient Therapeutics, Ltd.
Phase 2
115
California, Connecticut, Massachusetts, New York, Virginia
2025-03-28
Recruiting
Eli Lilly and Company
Phase 2
200
Arizona, California, Florida, Georgia, Idaho, Indiana, New Jersey, New York
2025-03-28
Recruiting
Daiichi Sankyo
Phase 3
510
Arizona, California, Michigan, Minnesota, Missouri, New Jersey, New York, Pennsylvania
2025-03-27
Active, closed
MiRus
Not applicable
30
California, Florida, Georgia, Minnesota, New Jersey, New York, Ohio
2025-03-26
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2/3
150
California, Illinois, Iowa, Maryland, New York, Pennsylvania
2025-03-25
Recruiting
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
NCT06810544Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor
Tango Therapeutics, Inc.
Phase 1/2
191
Arizona, California, District of Columbia, Florida, Illinois, Massachusetts, Minnesota, New York
2025-03-24
Recruiting
Auxilium Biotechnologies
Not applicable
80
California, Maryland, New York, Ohio, Pennsylvania, Texas
2025-03-21
Recruiting
Accent Therapeutics
Phase 1/2
218
Colorado, Florida, Michigan, Missouri, Nebraska, New York, Tennessee, Texas
2025-03-21
Recruiting
Bayer
Phase 1/2
450
Alabama, California, Colorado, Florida, Massachusetts, Michigan, New York, Tennessee
2025-03-21
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
206
California, Colorado, Florida, Georgia, Indiana, Michigan, Nebraska, New York
2025-03-21
Active, closed
TrueBinding, Inc.
Phase 2
62
California, Colorado, Florida, Illinois, Indiana, Kansas, Michigan, New York
2025-03-20
Recruiting
Medtronic Cardiac Ablation Solutions
Not applicable
60
Massachusetts, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-03-18
Recruiting
Diakonos Oncology Corporation
Phase 2
180
Arizona, California, Florida, Massachusetts, New Jersey, New York, North Carolina, Ohio
2025-03-17
Recruiting
Bristol-Myers Squibb
Phase 3
60
California, Illinois, Indiana, New York, Ohio, Texas
2025-03-13
Active, closed
Vir Biotechnology, Inc.
Phase 3
124
Arizona, California, Florida, Illinois, Maryland, New Jersey, New York, Utah
2025-03-12
Active, closed
AstraZeneca
Phase 2
82
Arizona, California, District of Columbia, Maryland, Massachusetts, Minnesota, New Jersey, New York
2025-03-12
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
Merck Sharp & Dohme LLC
Phase 2
308
California, Colorado, Florida, Illinois, Louisiana, Missouri, Nebraska, New York
2025-03-11
Active, closed
Abdera Therapeutics Inc.
Phase 1
17
California, Florida, Maryland, Massachusetts, Minnesota, New York, Texas, Utah
2025-03-10
Recruiting
Parent-Child EF Intervention
NCT06924307Cognitive Intervention to Promote Healthy Development of Executive Function (EF) Skills in Young Children
Koronis Biomedical Technologies
Not applicable
140
Minnesota, New York
2025-03-10
Recruiting
AstraZeneca
Phase 1
136
California, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Nebraska, New York
2025-03-10
Recruiting
A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06716138Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Avistone Biotechnology Co., Ltd.
Phase 1
96
New York
2025-03-06
Recruiting
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT06835569Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
Alterome Therapeutics, Inc.
Phase 1
448
Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee, Texas, Virginia
2025-03-05
Recruiting
Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1
NCT06714253Radiation-Induced Xerostomia and Hyposalivation
RiboX Therapeutics Ltd.
Phase 1/2
42
California, Iowa, Maryland, New York, Pennsylvania
2025-03-05
Recruiting
GlaxoSmithKline
Phase 1/2
305
California, Colorado, New York, North Carolina, Ohio
2025-03-04
Active, closed
BicycleTx Limited
Phase 2
66
Maryland, Massachusetts, Missouri, New York, North Carolina, Oregon, Texas, Virginia
2025-03-03
Active, closed
Dasher Neuroscience Inc.
Phase 2
75
California, Massachusetts, Minnesota, New York, Tennessee, Texas
2025-03-03
Recruiting
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
NCT06517875Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
GlaxoSmithKline
Phase 2
68
Michigan, New York, Tennessee, Texas, Washington
2025-02-28
Active, closed
Sanofi Pasteur, a Sanofi Company
Phase 3
1,268
California, Florida, Georgia, Iowa, Kentucky, Mississippi, Nebraska, New York
2025-02-28
Recruiting
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma
Clasp Therapeutics, Inc.
Phase 1
90
Arizona, California, Florida, Illinois, Kentucky, Maryland, New Jersey, New York
2025-02-28
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
327
Colorado, Florida, Illinois, Massachusetts, New Jersey, New York, Oregon, Tennessee
2025-02-27
Recruiting
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
NCT06816992Solid Tumors, EGFR Exon 20 Insertion Mutations, NSCLC, EGFR-mutated NSCLC
ORIC Pharmaceuticals
Phase 1
76
New York, Virginia
2025-02-27
Recruiting
Bambusa Therapeutics
Phase 1
237
California, New York
2025-02-27
Active, closed
Sanofi
Phase 3
580
California, Florida, Iowa, Kentucky, Louisiana, New York, Pennsylvania, South Carolina
2025-02-27
Recruiting
Daiichi Sankyo
Phase 3
726
Connecticut, Illinois, Kansas, Maryland, Massachusetts, Michigan, Minnesota, New York
2025-02-27
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Florida, Georgia, Louisiana, Massachusetts, New Jersey, New York, Tennessee, Texas
2025-02-26
Active, closed
Amgen
Phase 2
252
California, Connecticut, Florida, Illinois, Minnesota, New York, North Carolina, Pennsylvania
2025-02-26
Active, closed
Pfizer
Observational
1
New York
2025-02-24
Recruiting
Targeted Therapy Technologies, LLC
Phase 2
30
New York, Wisconsin
2025-02-21
Recruiting
Lumenis Be Ltd.
Not applicable
40
New York
2025-02-21
By invitation
Assess the Utility of a Speech-based Machine Learning Algorithm to Predict Treatment Response to Psychiatric Interventions
NCT06823024Obsessive Compulsive Disorder (OCD), Bipolar Disorders, Major Depressive Disorder, Post-Traumatic Stress Disorder, PTSD
Psyrin Inc.
Observational
200
California, New York
2025-02-18
Active, closed
Essilor International
Not applicable
91
Illinois, Kansas, Massachusetts, New York
2025-02-18
Recruiting
Bristol-Myers Squibb
Phase 1/2
286
California, Colorado, New Jersey, New York, North Carolina, Washington
2025-02-17
Recruiting
OurRelationship
Not applicable
120
Georgia, Maryland, New York, South Carolina, Texas
2025-02-15
Recruiting
March Biosciences Inc
Phase 2
46
California, Colorado, Florida, Iowa, Massachusetts, Nebraska, New York, North Carolina
2025-02-15
Recruiting
A Study of MGC028 in Participants With Advanced Solid Tumors
NCT06723236Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma
MacroGenics
Phase 1
124
California, Massachusetts, Michigan, New York, Texas, Utah
2025-02-13
Recruiting
MOTION Clinical Trial
NCT06843980Osteoarthritis, Knee
Moximed
Not applicable
100
California, Illinois, Nebraska, New York, Ohio, Texas
2025-02-13
Active, closed
Sanofi
Phase 3
231
California, Florida, Georgia, Idaho, Illinois, Indiana, Missouri, New York
2025-02-12
Active, closed
ConvaTec Inc.
Not applicable
235
California, Florida, Indiana, Maryland, Massachusetts, New York, North Carolina, Pennsylvania
2025-02-12
Recruiting
Evaluation of a Switchable Acrylic Adhesive Drape for Safer Removal in Negative Pressure Wound Therapy Applications.
NCT06717308Frequency and Type of Medical Adhesive-Related Skin Injury, NPWT Drape Seal Effectiveness Rate (or Leak Incidence Rate), Clinician Acceptability of New NPWT Drape, Patient Drop-out Rate From Prescribed NPWT Treatment
Global Biomedical Technologies, LLC
Not applicable
300
California, Florida, New York, Ohio
2025-02-10
Active, closed
Rivermark Medical
Not applicable
215
California, Colorado, Florida, Illinois, Louisiana, Michigan, Nevada, New York
2025-02-10
Recruiting
Janssen Research & Development, LLC
Phase 1/2
190
Colorado, Connecticut, Florida, Louisiana, Massachusetts, Michigan, Nebraska, New York
2025-02-06
Recruiting
Sequenom, Inc.
Observational
6,550
Arizona, Delaware, Florida, Louisiana, Massachusetts, New Jersey, New York, North Carolina
2025-02-02
Recruiting
Pediatric Down Syndrome Post-Approval Study
NCT06851338Pediatric Obstructive Sleep Apnea, Down Syndrome (DS)
Inspire Medical Systems, Inc.
Not applicable
60
Arizona, California, Florida, New York, Ohio, Texas
2025-02
By invitation
Follow-Up for Study Participants Treated With an Allogeneic CAR T Cell Product
NCT06925685Hematologic Malignancies, Solid Tumors
Allogene Therapeutics
Observational
50
New York
2025-01-31
Recruiting
Allotera Therapeutics
Phase 2
125
California, Colorado, District of Columbia, Florida, Georgia, Missouri, New York, Ohio
2025-01-31
Recruiting
BOOM-IBD2 Pivotal Clinical Trial
NCT06571669Ulcerative Colitis, Inflammatory Bowel Diseases
Boomerang Medical
Not applicable
137
California, Kansas, Minnesota, Mississippi, Missouri, Nevada, New York, North Carolina
2025-01-31
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
AstraZeneca
Phase 1/2
408
Massachusetts, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Rhode Island
2025-01-30
Recruiting
Tissue Repair Gel in Venous Leg Ulcers (US)
NCT06707090Venous Leg Ulcer, Venous Ulcer, Venous Stasis Ulcer, Venous Stasis
TR Therapeutics
Phase 3
312
Arizona, California, Florida, Illinois, Louisiana, Mississippi, New York, North Carolina
2025-01-28
Recruiting
Zomagen Biosciences Ltd.
Phase 2
50
California, Florida, Illinois, Massachusetts, Minnesota, New York, Ohio, Texas
2025-01-28
Active, closed
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
NCT06781983Advanced or Metastatic Solid Tumors
Innate Pharma
Phase 1
145
Massachusetts, New Jersey, New York, Texas, Virginia
2025-01-24
Recruiting
Neurocrine Biosciences
Phase 3
200
Arkansas, California, Florida, Massachusetts, New York, Ohio, Texas, Washington
2025-01-22
Recruiting
Takeda
Phase 3
70
Arizona, California, Illinois, Michigan, New Jersey, New York, Ohio, Oklahoma
2025-01-22
Recruiting
Cullinan Therapeutics Inc.
Phase 1
24
Arizona, Florida, Iowa, Massachusetts, New York, Tennessee, Texas, Utah
2025-01-21
Active, closed
Pfizer
Observational
22,234,435
New York
2025-01-20
Recruiting
Pfizer
Observational
600
New York
2025-01-20
Recruiting
Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
NCT06182397Arterial Disease of Legs, Below-the-knee Obstruction, PAD - Peripheral Arterial Disease
Concept Medical Inc.
Not applicable
368
Arizona, California, Florida, Iowa, Michigan, New Jersey, New York, Ohio
2025-01-16
Not yet open
Natural Heart Health Supplement Trial
NCT06671769Cholesterol, Cholesterol (total and HDL)
Efforia, Inc
Phase 1
60
New York
2025-01-15
Recruiting
AOTI Ltd.
Phase 4
212
New York
2025-01-15
Active, closed
Intellia Therapeutics
Phase 3
80
Arizona, California, Colorado, Florida, Massachusetts, Missouri, New York, Ohio
2025-01-15
Active, closed
Stemline Therapeutics, Inc.
Phase 2
85
California, Florida, Illinois, Massachusetts, Michigan, Missouri, New Jersey, New York
2025-01-14
Recruiting
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer
Jazz Pharmaceuticals
Phase 2
200
Arizona, Colorado, Florida, Illinois, Kansas, Michigan, New York, Pennsylvania
2025-01-14
Recruiting
BeOne Medicines
Phase 1
695
California, Florida, Massachusetts, Missouri, New York, Pennsylvania, Tennessee, Texas
2025-01-10
Recruiting
Praxis Precision Medicines
Phase 2
50
Arizona, Florida, Maryland, Missouri, New Jersey, New York, Texas
2025-01-10
Recruiting
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963Ovarian Cancer, Breast Cancer, Endometrial Cancer, Non-Small Cell Lung Cancer
LigaChem Biosciences, Inc.
Phase 1
145
California, Kentucky, Massachusetts, Missouri, New Jersey, New York, Ohio, Pennsylvania
2025-01-07
Active, closed
Daiichi Sankyo
Phase 2
335
Georgia, Michigan, New Jersey, New York, Tennessee, Texas
2025-01-06
Recruiting
SpectraCure AB
Phase 1/2
43
New York
2025-01-06
Active, closed
Cochlear
Not applicable
56
California, Colorado, Iowa, Michigan, Missouri, New York, Ohio, Oregon
2025-01-03
Recruiting
Takeda
Phase 3
396
California, Colorado, Florida, Indiana, Kentucky, New York, South Carolina, South Dakota
2025-01-02
Recruiting
InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS
NCT05960929Respiratory Distress Syndrome (Neonatal), Intubation Complication, Death; Neonatal
ONY
Phase 3
220
Arizona, California, Florida, Hawaii, New Jersey, New York, Tennessee, Utah
2025-01-01
Recruiting
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
NCT06600321Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Alnylam Pharmaceuticals
Phase 1
158
Arizona, California, Florida, Georgia, Illinois, Michigan, Minnesota, New York
2024-12-30
Active, closed
Boehringer Ingelheim
Phase 2
90
California, Connecticut, Florida, Missouri, Nebraska, New York, Tennessee, Texas
2024-12-30
Recruiting
Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)
NCT06805695Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Urea Cycle Disorders, Inborn
iECURE, Inc.
Observational
13
Colorado, New York
2024-12-23
Recruiting
The Lily Device Trial
NCT06786078Chemotherapy Induced Alopecia
Luminate Medical, Inc.
Not applicable
85
New Jersey, New York, Pennsylvania
2024-12-20
Active, closed
AbbVie
Phase 2
83
Arizona, California, Colorado, Florida, Illinois, Nebraska, New York, Oregon
2024-12-19
Recruiting
Sumitomo Pharma America, Inc.
Phase 1/2
25
California, Kentucky, New York
2024-12-18
Recruiting
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
NCT06656494Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
266
California, Connecticut, Florida, New York, North Carolina, Wisconsin
2024-12-18
Recruiting
Cabaletta Bio
Phase 1/2
24
California, Colorado, Florida, Illinois, Kansas, Massachusetts, Minnesota, New York
2024-12-17
Recruiting
AbbVie
Phase 3
231
Alabama, Arizona, California, Florida, Georgia, Louisiana, Maryland, New York
2024-12-16
Recruiting
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
NCT06784193Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer
Olema Oncology, Inc.
Phase 1
180
Arizona, Colorado, Florida, Louisiana, Massachusetts, Michigan, New York, Ohio
2024-12-16
Recruiting
ViewFlex X ICE First-in-Human Study
NCT06772493Cardiac Arrhythmias
Abbott Medical Devices
Observational
500
Arkansas, California, Florida, Missouri, New York, Pennsylvania, South Carolina, Texas
2024-12-16
Recruiting
The PERSEVERE Study
NCT06588634Pulmonary Embolism, Pulmonary Thromboembolism
Inari Medical
Not applicable
200
Connecticut, Florida, Georgia, Mississippi, New Jersey, New York, Ohio, Pennsylvania
2024-12-16
Active, closed
Treeline Biosciences, Inc.
Phase 1
50
California, Missouri, New York, Tennessee
2024-12-16
Active, closed
Microtech Medical Technologies, Ltd
Not applicable
15
New York
2024-12-15
Recruiting
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
NCT06657222Advanced Solid Tumors, HNSCC, SCLC, NSCLC
Gilead Sciences
Phase 1/2
250
Connecticut, Florida, Massachusetts, Minnesota, Missouri, New York, Ohio, Texas
2024-12-13
Active, closed
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
NCT06750432Alzheimer Disease, Early Onset
ProMis Neurosciences, Inc
Phase 1
144
California, Florida, Georgia, Massachusetts, New Jersey, New York, North Carolina, Ohio
2024-12-13
Active, closed
GlaxoSmithKline
Phase 1/2
14
California, Colorado, Michigan, New York, Pennsylvania
2024-12-13
Recruiting
Faeth Therapeutics
Phase 2
40
California, Florida, Maryland, Minnesota, New York, Ohio, Oregon, Pennsylvania
2024-12-12
Recruiting
Boehringer Ingelheim
Phase 2
80
Arizona, Colorado, Florida, Illinois, Kansas, New York, North Carolina, Texas
2024-12-11
Recruiting
Deciphera Pharmaceuticals, LLC
Phase 1/2
155
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Minnesota, New York
2024-12-10
Recruiting
Novartis Pharmaceuticals
Phase 3
60
California, District of Columbia, Florida, New York, Utah, Virginia, West Virginia
2024-12-09
Active, closed
The JenaValve ALIGN-AR LVAD Registry
NCT06594705Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency, Aortic Valve Disease
JenaValve Technology, Inc.
Not applicable
50
California, District of Columbia, Georgia, Illinois, Michigan, Minnesota, Missouri, New York
2024-12-09
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 2
130
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New Jersey, New York
2024-12-06
Recruiting
SNIPR Biome Aps.
Phase 1/2
66
California, Maryland, Massachusetts, Minnesota, New York, Pennsylvania, Texas, Washington
2024-12-04
Recruiting
Novo Nordisk A/S
Phase 2
465
California, Colorado, Florida, Illinois, Indiana, Michigan, Missouri, New York
2024-12-02
Active, closed
AIQ Solutions
Not applicable
25
New York, Texas
2024-12-02
Recruiting
BeOne Medicines
Phase 1/2
80
Arizona, California, Florida, Kansas, Minnesota, Missouri, New York, Pennsylvania
2024-11-27
Active, closed
AbbVie
Observational
1,314
Alabama, Arizona, California, Florida, Kentucky, New York, Pennsylvania, Virginia
2024-11-26
Recruiting
Adcendo ApS
Phase 1
210
Arkansas, Connecticut, Massachusetts, Missouri, New York, Texas
2024-11-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,380
Connecticut, Michigan, Missouri, New York, Texas, Virginia, Washington
2024-11-25
Recruiting
RTI Surgical
Not applicable
467
Arkansas, California, Colorado, Kansas, Missouri, New York, Ohio, Oklahoma
2024-11-22
Recruiting
Intra-Cellular Therapies, Inc.
Phase 2
570
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Mississippi, New York
2024-11-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
67
California, Illinois, New York, Ohio
2024-11-21
Recruiting
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
NCT06458712Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)
Duke Street Bio Ltd
Phase 1
180
California, Connecticut, New York, Texas
2024-11-21
Recruiting
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
NCT06699056Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement
Peerbridge Health, Inc
Observational
2,000
California, Michigan, New Jersey, New York, North Carolina, Texas
2024-11-21
Active, closed
Avalus Ultra Post-Approval Study (PAS)
NCT06506903Aortic Valve Disease
Medtronic Cardiac Surgery
Not applicable
190
Connecticut, Florida, Georgia, Illinois, Michigan, Minnesota, New York, Ohio
2024-11-20
Active, closed
GlaxoSmithKline
Phase 1/2
465
Kansas, Louisiana, New Jersey, New York, Pennsylvania, Texas, Washington
2024-11-19
Recruiting
Day One Biopharmaceuticals, Inc.
Phase 1
300
Connecticut, Florida, Indiana, Michigan, New York, Oklahoma, Tennessee, Texas
2024-11-18
By invitation
Integra LifeSciences Corporation
Not applicable
350
California, Connecticut, Florida, Georgia, Illinois, Louisiana, Maryland, New York
2024-11-18
Active, closed
Stryker Facial iD Universal Plate Configurator: A Retrospective Post Market Follow Up
NCT07245810Mandibular Fractures, Facial Fracture, Maxilla Fracture, Orthognathic Surgical Procedures
Stryker Craniomaxillofacial
Observational
726
New York
2024-11-18
Recruiting
E-Star BioTech, LLC
Phase 2
120
Arkansas, California, Florida, Georgia, Illinois, Michigan, Mississippi, New York
2024-11-17
Recruiting
Genentech, Inc.
Phase 1
410
California, Colorado, Connecticut, Florida, Illinois, Massachusetts, Michigan, New York
2024-11-14
Recruiting
Neurona Therapeutics
Phase 1/2
10
Arkansas, California, Colorado, Illinois, Iowa, New York, North Carolina, Oregon
2024-11-14
Recruiting
Daiichi Sankyo
Phase 1
150
Massachusetts, New York, Tennessee
2024-11-14
Active, closed
Inventprise Inc.
Phase 1/2
600
New York
2024-11-12
Active, closed
GlaxoSmithKline
Phase 2
283
California, Minnesota, New York, Pennsylvania
2024-11-11
By invitation
A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
NCT06375993Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)
Adicet Therapeutics
Phase 1
180
California, New York
2024-11-10
Recruiting
Anti-GD2 ADC M3554 in Advanced Solid Tumors
NCT06641908Advanced Solid Tumor
EMD Serono Research & Development Institute, Inc.
Phase 1
65
Massachusetts, New York, Texas
2024-11-08
Active, closed
Takeda
Phase 3
53
California, Colorado, Florida, Georgia, Illinois, Louisiana, New York, North Carolina
2024-11-04
Recruiting
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
NCT06733935Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis
Nkarta, Inc.
Phase 1/2
240
California, Florida, Kansas, Michigan, Minnesota, New Jersey, New York, North Carolina
2024-11-04
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
180
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Nevada, New York
2024-11-03
Recruiting
Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing
NCT06939686Diabetic Foot Ulcers (DFUs), Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer)
Reprise Biomedical, Inc.
Not applicable
30
Florida, New York
2024-11-01
Recruiting
Coherus Oncology, Inc.
Phase 4
100
Arkansas, California, Georgia, Massachusetts, Michigan, New York, Ohio, Pennsylvania
2024-11-01
Recruiting
Renovo Concepts, Inc.
Not applicable
11
New York, North Carolina, West Virginia
2024-11-01
Active, closed
MBX Biosciences
Phase 2
60
Florida, Georgia, Mississippi, Missouri, Nevada, New York, Ohio, Texas
2024-10-31
Recruiting
Serrantor OCT Study
NCT06434194Critical Limb Ischemia
Cagent Vascular LLC
Not applicable
60
New York
2024-10-31
Recruiting
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
NCT06451770Hypercholesterolemia, Hypertriglyceridemia, Refractory Hyperlipidemia
Eli Lilly and Company
Phase 1
132
California, Florida, New York
2024-10-30
Active, closed
Boston Scientific Corporation
Not applicable
230
California, Florida, Georgia, Illinois, Kansas, New York, Ohio, Pennsylvania
2024-10-30
Active, closed
Daiichi Sankyo
Phase 1/2
137
California, Florida, Kentucky, Minnesota, New York, Pennsylvania, Virginia
2024-10-30
Recruiting
Iovance Biotherapeutics, Inc.
Phase 2
60
Arizona, California, Florida, Georgia, Kentucky, Michigan, New York, Oklahoma
2024-10-29
Recruiting
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT06625775Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
392
California, Florida, Indiana, Massachusetts, Missouri, New York, Tennessee, Texas
2024-10-29
Recruiting
Rapid Medical
Observational
424
California, Michigan, New York, Pennsylvania
2024-10-28
Active, closed
Denali Therapeutics Inc.
Phase 2
50
California, Florida, Massachusetts, New York, Washington
2024-10-24
Active, closed
Amgen
Phase 3
19
Georgia, Indiana, Minnesota, New York, North Carolina, Ohio, Pennsylvania, Texas
2024-10-22
Active, closed
Pfizer
Phase 3
900
Arizona, Arkansas, California, Illinois, New York, Washington
2024-10-22
Active, closed
Abcuro, Inc.
Phase 2/3
270
Arizona, California, Connecticut, Massachusetts, New York, North Carolina, Ohio, Pennsylvania
2024-10-21
Active, closed
Novartis Pharmaceuticals
Phase 2
251
California, Florida, Georgia, Kansas, Massachusetts, Nebraska, New York, North Carolina
2024-10-17
By invitation
Adenocyte, LLC
Observational
500
New York
2024-10-15
Active, closed
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
NCT06553768Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Mirum Pharmaceuticals, Inc.
Phase 3
90
California, Illinois, New York, Ohio, Texas, Utah
2024-10-14
Active, closed
Ipsen
Observational
424
California, Colorado, Connecticut, Florida, Massachusetts, New Jersey, New York, North Carolina
2024-10-14
Active, closed
Merck Sharp & Dohme LLC
Phase 2
66
Iowa, Nevada, New York
2024-10-14
Recruiting
Xencor, Inc.
Phase 1/2
270
Arizona, California, Florida, Kentucky, Mississippi, New York, North Carolina, Ohio
2024-10-10
Active, closed
Sonoma Biotherapeutics, Inc.
Phase 1
24
Massachusetts, Minnesota, Missouri, New York, North Carolina, Texas
2024-10-09
Active, closed
Novartis Pharmaceuticals
Phase 2
203
Arizona, California, Florida, Illinois, Michigan, New York, Tennessee, Texas
2024-10-09
Recruiting
Study of ACR-2316 in Specific Advanced Solid Tumors
NCT06667141Specific Advanced Solid Tumors
Acrivon Therapeutics
Phase 1/2
100
Arizona, California, Colorado, Florida, Massachusetts, Michigan, New York, North Carolina
2024-10-08
Active, closed
AbbVie
Phase 2
309
Alabama, Arizona, California, Florida, New Mexico, New York, Oklahoma, Pennsylvania
2024-10-07
Active, closed
Boston Scientific Corporation
Phase 3
20
Arizona, California, Georgia, Michigan, New York, Ohio, Pennsylvania, Rhode Island
2024-10-07
Active, closed
AstraZeneca
Phase 3
768
Arkansas, California, Florida, Missouri, New York, Ohio, Pennsylvania, Tennessee
2024-10-04
Recruiting
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
NCT06625671Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus
DualityBio Inc.
Phase 1/2
148
California, Florida, New York, Texas
2024-10-04
Recruiting
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
NCT05947955Acute Respiratory Distress Syndrome, Infections
BioAegis Therapeutics Inc.
Phase 2
600
California, Georgia, Illinois, Kentucky, Minnesota, Missouri, New York, Pennsylvania
2024-10-03
Recruiting
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Phase 1
256
California, Florida, Kansas, Massachusetts, Michigan, Missouri, New York, North Carolina
2024-10-03
Recruiting
R3 Medical Research
Early Phase 1
120
Arizona, California, New York, Texas
2024-10-01
Recruiting
VIS, Inc.
Phase 3
75
Florida, Massachusetts, New Jersey, New York
2024-09-30
By invitation
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients
NCT06657859Pmm2-CDG, Phosphomannomutase 2 Deficiency
Glycomine, Inc.
Phase 2
90
Minnesota, New York, Pennsylvania, Washington
2024-09-30
Active, closed
Jenscare Innovation Inc.
Not applicable
15
California, Michigan, New York
2024-09-26
Recruiting
GAP Innovations, PBC
Observational
1,200
Florida, Illinois, Michigan, Nevada, New York, Ohio, Pennsylvania, Rhode Island
2024-09-26
Active, closed
A Multi-Centre Study in Patients Undergoing Total Hip Arthroplasty With the Smith+Nephew CATALYSTEM™ Primary Hip System
NCT06564636Total Hip Arthroplasty (THA), Osteoarthritis, Degenerative Joint Disease, Inflammatory Arthritis
Smith & Nephew, Inc.
Observational
119
California, Connecticut, Florida, Illinois, New York, North Carolina
2024-09-26
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
240
California, Connecticut, Illinois, Michigan, New York, North Carolina, Pennsylvania, Texas
2024-09-23
Rows per page Showing 501–1000 of 2118
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 November 2026. https://priyalifescience.com/clinical-trials-usa/state/new-york?page=2

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,148 studies in total at the last sync on 22 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,118 of those studies with a site in New York.

How many clinical trials are recruiting in New York?

1,134 of the 2,118 studies on this page are recruiting new participants as of the 22 Nov 2026, 03:16 UTC sync. A further 57 have not yet opened recruitment, 837 are active but closed to new participants, and 90 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.